From Breakthrough to Blockbuster
New book co-authored by Nektarios Oraiopoulos of Cambridge Judge Business School charts the rise of entrepreneurial biotech firms. Dr Nektarios Oraiopoulos From Breakthrough to Blockbuster: The Business of Biotechnology, published today, shows how the small, inexperienced entrepreneurial companies making up…
Business Weekly: Qureight secures £1.5m to enhance AI solution in battle against complex diseases
Cambridge-based Qureight, a clinical data curation and analytics company, has raised £1.5 million seed funding to develop AI-powered platform allowing to collect data from complex diseases. “Qureight’s platform technology will allow biopharma companies to recruit fewer patients for clinical trials…
Carryover co-operation
Sir Mene Pangalos of AstraZeneca, in a Cambridge Judge interview, urges continuation of the 'exceptional' collaboration between industry, academia, government and regulators that led to rapid development of COVID-19 vaccines. Sir Mene Pangalos The "exceptional" collaboration between the pharmaceutical industry,…
Forbes India: How drug companies can increase their R&D effectiveness
A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…
Pharma shift
The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…
Investing in Cambridge drug discovery
PharmEnable raises £1.8 million for drug discovery expansion. PharmEnable, a venture supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, said it has secured £1.8 million in a seed financing round led by Cambridge…
Biotech vs big pharma
Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…
Manhattan Project?
A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…
Drug trials
An Executive MBA alumnus, Dr Rav Seeruthun, heads a Roche team that has developed a drug being tested to fight COVID-19. Dr Rav Seeruthun (EMBA 2013) of Cambridge Judge Business School, is heading a team at the Roche UK Medical Directorate that has developed…
Fast Company: How open-source medicine could prepare us for the next pandemic
A study on drug repurposing co-authored by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. The study found that “about 31 per cent of drugs approved by the FDA had…